Ahorro del sistema de salud por la regulación directa de precios de venta de medicamentos biotecnológicos en Colombia

We developed a retrospective analysis on the sales of thirteen biotechnological regulated medi-cines between June, 2010, and June, 2014, in two scenarios: Amounts billed after the price and assumed value regulation, calculated based on the average sale price during the six months prior to the regulation, plus the health consumer price index. The difference between both scenarios entails a saving for the system. The biotechnological medicines analyzed generated savings for US $95 Million in said period; 10.2% during the first year, 17.2% during the second, and 30.5% during the third. The biotechnological medicine that generated the most savings was rituximab (40.9%), equivalent to US $38,510,787. The direct regulation of biotechnological medicines has generated significant savings for the healthcare system, as seen from the sales registered by Audifarma. Probably, the economic savings generated by this policy are above the initial government estimates.

• Autores: Sánchez-Villalobos O.; Mesa-Escobar G.H.; Ruíz-Correa A.F.; Quintero Ortiz, Diego Nadin; López S.L.; Serna-Guerrero J.S.; Muñoz-Díaz P.A.
• Tipo de recurso: Article of journal
• Fecha de publicación: 2016
• Institución: Universidad Cooperativa de Colombia
• Repositorio: Repositorio UCC
• OAI Identifier: oai:repository.ucc.edu.co:20.500.12494/41776
• Acceso en línea: https://doi.org/10.1590/2175-35392018039914; http://ojs.urepublicana.edu.co/index.php/pensamientorepublicano/article/view/423/389; https://hdl.handle.net/20.500.12494/41776
• Palabra clave: Biotechnology; Cost control; Economic analysis; Health economy; Medical savings; Product marketing
• Rights: closedAccess
• License: http://purl.org/coar/access_right/c_14cb